延长目标温度管理损害凝血酶生成:一项随机临床试验
该随机临床试验纳入82例院外心脏骤停后昏迷幸存者,比较标准24小时与延长48小时目标温度管理(33±1°C)对凝血的影响。在达到目标温度后22、46和70小时采血,行旋转血栓弹力图和凝血酶生成检测。46小时样本显示延长组凝血酶生成减少:滞后时间延长30%、峰值浓度降低106nM、达峰时间延长36%、内源性凝血酶潜能降低411 nM*minute。结论为延长目标温度管理损害心脏骤停后患者的凝血酶生成。
要点
- 院外心脏骤停后昏迷患者延长目标温度管理至48小时较24小时标准时长在46小时血样时凝血酶生成减少。
- 46小时样本延长组较标准组滞后时间延长30%(p=0.04)、峰值浓度降低106nM(p<0.001)。
- 46小时样本延长组较标准组达峰时间延长36%(p=0.01)、内源性凝血酶潜能降低411 nM*minute(p<0.001)。
- 46小时样本INTEM®显示延长组较标准组凝血时间延长11%(p<0.01)、达最大速度时间延长12%(p<0.01)。
- 70小时样本延长组较标准组仍见滞后时间延长、峰值浓度降低和达峰时间延长(所有p值≤0.02)。
适用人群与场景
- 院外心脏骤停后昏迷幸存者(n=82),随机接受标准24小时或延长48小时目标温度管理,目标温度33±1°C。
处置流程与药物剂量
- 目标温度管理目标温度33±1°C,标准时长为24小时,延长时长为48小时。
- 达到目标温度后22、46和70小时采血,行旋转血栓弹力图(ROTEM®的EXTEM®、INTEM®、FIBTEM®和HEPTEM®)和校准自动凝血酶生成检测(Calibrated Automated Thrombogram®)。
研究设计与关键结果
- 随机对照试验纳入82例院外心脏骤停后昏迷幸存者,比较标准24小时与延长48小时目标温度管理(33±1°C)。
- 22小时样本:除延长组EXTEM®和INTEM®最大速度略高外(p值≤0.04),两组ROTEM®和凝血酶生成结果无差异。
- 46小时样本:EXTEM®无差异;INTEM®示延长组较标准组凝血时间延长11%(p<0.01)、达最大速度时间延长12%(p<0.01)。
- 46小时样本:延长组较标准组凝血酶生成减少,滞后时间延长30%(p=0.04)、峰值浓度降低106nM(p<0.001)、达峰时间延长36%(p=0.01)、内源性凝血酶潜能降低411 nM*minute(p<0.001)。
- 70小时样本:两组ROTEM®结果无差异;延长组较标准组凝血酶生成减少,表现为滞后时间延长、峰值浓度降低和达峰时间延长(所有p值≤0.02)。
证据类型、等级与局限
- 证据类型:随机对照试验(ClinicalTrials.gov标识NCT02258360)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论为心脏骤停后患者延长目标温度管理损害凝血酶生成。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To investigate whether prolonged compared with standard duration of targeted temperature management (TTM) compromises coagulation.
METHODS: Comatose survivors after out-of-hospital cardiac arrest (n=82) were randomised to standard (24h) or prolonged (48h) duration of TTM at 33±1°C. Blood samples were drawn 22, 46 and 70h after attaining the target temperature. Samples were analysed for rotational thromboelastometry (ROTEM® (EXTEM®, INTEM®, FIBTEM® and HEPTEM®)) and thrombin generation using the Calibrated Automated Thrombogram® assay.
RESULTS: With the 22-h sample, we revealed no difference between groups in the ROTEM® and thrombin generation results beside a slightly higher EXTEM® and INTEM® maximum velocity in the prolonged group (p-values≤0.04). With the 46-h sample, ROTEM® showed no differences when using EXTEM®; however, 11% (p<0.01) longer clotting time and 12% (p<0.01) longer time to maximum velocity were evident in the prolonged group than in the standard group when using INTEM®. The prolonged group had reduced thrombin generation compared with the standard group as indicated by 30% longer lag time (p=0.04), 106nM decreased peak concentration (p<0.001), 36% longer time to peak (p=0.01) and 411 nM*minute decreased endogenous thrombin potential (p<0.001). With the 70-h sample, no differences in ROTEM® results were found between groups. However, the prolonged group had reduced thrombin generation indicated by longer lag time, decreased peak concentration and longer time to peak (all p-values≤0.02) compared with the standard group.
CONCLUSION: Prolonged TTM in post-cardiac arrest patients impairs thrombin generation. ClinicalTrials.gov identifier: NCT02258360.
参考来源
- Jeppesen AN, Hvas AM, Duez CHV, et al. Prolonged targeted temperature management compromises thrombin generation: A randomised clinical trial. Resuscitation. 2017. PMID: 28602694. doi:10.1016/j.resuscitation.2017.06.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。